Tonix Pharmaceuticals Announces Outcome of Interim Analysis of Phase 3 RALLY Study of TNX-102 SL for the Management of Fibromyalgia

Go back to Tonix Pharmaceuticals Announces Outcome of Interim Analysis of Phase 3 RALLY Study of TNX-102 SL for the Management of Fibromyalgia
TONIX PHARM HLDG (NASDAQ: TNXP) Delayed: 12.83 --0 (-0%)
Previous Close $12.83    52 Week High $7.95 
Open $12.83    52 Week Low $0.40 
Day High $12.83    P/E N/A 
Day Low $12.83    EPS $-5.33 
Volume 1,242